Jeffrey Bander
Icahn School of Medicine at Mount Sinai
16 Papers
34 Citations
Jeffrey Bander is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 14 publications.
Chat about Author
Papers
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.
Sean T. H. Liu,Hung-Mo Lin,Ian Baine,Ania Wajnberg,Jeffrey P. Gumprecht,Farah Rahman,Denise Rodriguez,Pranai Tandon,Adel Bassily-Marcus,Jeffrey Bander,Charles Sanky,Amy C. Dupper,Allen Zheng,Freddy T. Nguyen,Fatima Amanat,Daniel Stadlbauer,Deena R. Altman,Benjamin K. Chen,Florian Krammer,Damodara Rao Mendu,Adolfo Firpo-Betancourt,Matthew A. Levin,Emilia Bagiella,Arturo Casadevall,Carlos Cordon-Cardo,Jeffrey S. Jhang,Suzanne Arinsburg,David Reich,Judith A. Aberg,Nicole M. Bouvier +29 more
TL;DR: Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
TL;DR: It is hypothesize that the benefits of treatment with renin-angiotensin system inhibitors in SARS-COV2 may outweigh the risks and at the very least should not be withheld.
156
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
Usman Baber,Jeffrey Bander,Rucha Karajgikar,Kapil Yadav,Ali Hadi,Kleanthis Theodoropolous,Nilusha Gukathasan,Swathi Roy,Swapna Sayeneni,Stuart A. Scott,Jason C. Kovacic,Jennifer Yu,Samantha Sartori,Roxana Mehran,Jaime Uribarri,Juan J. Badimon,Paul Muntner,Pedro Moreno,Annapoorna Kini,Samin K. Sharma +19 more
TL;DR: The presence of both CKD and DM confers a synergistic impact on residual platelet reactivity when compared to either condition alone, and more potent platelet inhibitors may improve outcomes among patients with both abnormalities warrants investigation.
40
Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
Jeffrey Bander,Sammy Elmariah,Louis M. Aledort,Jeffrey S. Dlott,Paul Stelzer,Jonathan L. Halperin,Annapoorna Kini,Samin K. Sharma +7 more
TL;DR: Both BAV and AVR reverse the haematological abnormalities of the acquired von Willebrand syndrome of AS and ADAMTS-13 levels decrease after AVR, suggesting that a portion of theHaematologic benefit of AVR may be due to a postoperative decline in ADAMts-13 rather than solely to relief of AS as previously thought.
27
Outcomes of Impella‐supported high‐risk nonemergent percutaneous coronary intervention in a large single‐center registry
Lorenzo Azzalini,Gurpreet S. Johal,Usman Baber,Jeffrey Bander,Pedro R. Moreno,Lucas Bazi,Vishal Kapur,Nitin Barman,Annapoorna Kini,Samin K. Sharma +9 more
TL;DR: The aim was to evaluate the early and one‐year outcomes of Impella‐supported high‐risk nonemergent percutaneous coronary intervention (PCI).
21